Rossari Biotech Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹544Cr
- +11% YoY
- −6.2% QoQ
- Net profit
- ₹34Cr
- −2.9% YoY
- 0% QoQ
- Margin
- 12%
- −1 pp YoY
- 0 pp QoQ
Guidance rank: #45 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Rossari Biotech expects mid-double-digit revenue growth of around 14%-15% annually over the next 2 years. Rossari Biotech expects mid-double-digit (14%-15%) growth in both revenue and EBITDA over the next 2 years (Page 8).
From Rossari Biotech Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Rossari Biotech expects mid-double-digit revenue growth of around 14%-15% annually over the next 2 years.
- Export sales are anticipated to make up approximately 27%-28% of overall turnover on an annualized basis.
- The Institutional Cleaning and Consumer Business vertical is expected to grow healthily on an annual basis, especially in subsequent quarters after Q1.
- The B2B business is projected to grow at a faster pace over the next 2-3 years once EO availability improves and new capacities attain optimal utilization.
- Volume growth in exports has been 11% YoY despite temporary disruptions, indicating robust demand.
2 more points from Rossari Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing capacity expansion projects across Rossari Biotech, Unitop Chemicals, and Tristar Intermediates progressing in phases.
- These expansions aim to eliminate capacity constraints, enhance supply chain agility, and strengthen positioning in high-growth sectors.
- Commissioning of new capacities expected in upcoming quarters, with full operation and optimal utilization anticipated by FY27, delivering 3x-4x asset turns.
- An overseas formulation facility is being set up in Southeast Asia with an initial CAPEX of around Rs. 15-20 crore to enhance international presence and customer engagement.
- Investments are funded through a mix of internal accruals and debt.
- CAPEX work impacted production temporarily due to safety protocols but is on track.
2 more points from Rossari Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- It was mentioned that some institutional orders are phased and expected to be fulfilled over the next couple of quarters, indicating a pipeline of pending orders.
- The Institutional Consumer business experienced a softer Q1 but is expected to show healthy growth on an annual basis.
- Q2 and Q3 are anticipated to be stronger quarters for fulfilling institutional orders.
2 more points from Rossari Biotech Ltd's call on order book
Create a free account to keep reading this call
Rossari Biotech Ltd — Quarterly revenue & net profit
Rossari Biotech Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 544 | 490 | +11% | 580 | -6.2% |
| Operating profit (EBITDA) | 68 | 65 | +4.6% | 69 | -1.4% |
| Operating margin | 12% | 13% | -1 pp | 12% | 0 pp |
| Profit before tax | 46 | 47 | -2.1% | 48 | -4.2% |
| Net profit (PAT) | 34 | 35 | -2.9% | 34 | 0% |
| EPS (₹) | 6.07 | 6.32 | -4% | 6.22 | -2.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹698 Cr, net profit ₹39 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rossari Biotech's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Balaji Amines (Q1 FY26)
Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25…
- Linde India (Q1 FY26)
Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key concall takeaways from Linde India Ltd's…
- Vidhi Specialty (Q1 FY26)
87.9 Crores . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals (Q1 FY26)
Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q1…
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rossari Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rossari Biotech Ltd Q1 FY26 results?
Rossari Biotech expects mid-double-digit revenue growth of around 14%-15% annually over the next 2 years. Rossari Biotech expects mid-double-digit (14%-15%) growth in both revenue and EBITDA over the next 2 years (Page 8).
What is Rossari Biotech Ltd share price analysis?
Rossari Biotech Ltd currently shows a neutral. The stock trades at a P/E of 18.5 with a market cap of ₹2,786 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rossari Biotech Ltd planning capital expenditure?
Ongoing capacity expansion projects across Rossari Biotech, Unitop Chemicals, and Tristar Intermediates progressing in phases.
Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
